<DOC>
	<DOCNO>NCT01639339</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability belimumab adult patient active lupus nephritis .</brief_summary>
	<brief_title>Efficacy Safety Belimumab Patients With Active Lupus Nephritis</brief_title>
	<detailed_description>Study participant receive standard therapy ( induction maintenance ) lupus nephritis addition receive either placebo ( active medicine ) belimumab . Induction therapy start first dose study drug ( belimumab placebo ) . Maintenance therapy begin completion induction therapy continue remainder study . Participants receive study drug throughout entire study , induction maintenance period . The controlled period study 104 week . The random assignment study `` 1 1 '' mean equal chance receive treatment belimumab placebo . Participants successfully complete 104-week study may enter 6-month open-label extension . All participant open-label extension receive belimumab .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis SLE American College Rheumatology ( ACR ) criterion . Biopsy confirm active lupus nephritis . Clinically active lupus renal disease screen require /receiving induction therapy Standard Care medication . Autoantibodypositive . Key Pregnant nursing . On dialysis within past year . Treatment belimumab within past year . Receipt induction therapy cyclophosphamide within 3 month prior induction therapy study . Receipt B cell target therapy ( example , rituximab ) , investigational biological agent within past year . Severe active central nervous system ( CNS ) lupus . Required management acute chronic infection within past 60 day . Current drug alcohol abuse dependence . Tested positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. History severe allergic reaction contrast agent biological medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Lupus</keyword>
	<keyword>Nephritis</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>SLE</keyword>
</DOC>